---

Pneumonia: A Comprehensive Clinical Overview

---

1. Definition

---

2. Classification

---

3. Epidemiology

• CAP accounts for 7 annual healthcare visits/1000 young adults but 96 visits/1000 adults ≥85 years — exponential increase with age
• Hospitalization rates: ~1–2/1000 in young adults → 40/1000 in those ≥85 years
• Seasonal peak: November–March (coincides with influenza and other respiratory viral surges)
• ~35% of CAP hospitalizations in the U.S. involve patients with recent healthcare exposure; ~25% have immunocompromising conditions
• Goldman-Cecil Medicine, p. 990

---

4. Etiology & Common Pathogens

Bacterial (most common causes of severe CAP)

Viral (up to 90% of pediatric pneumonias)

• SARS-CoV-2 (COVID-19), Influenza A/B, RSV, Human metapneumovirus, Parainfluenza, Adenovirus
• Characterized by inflammation predominantly confined to alveolar septa, with respiratory distress often out of proportion to radiologic signs
• Robbins & Kumar Basic Pathology, p. 497

---

5. Pathogenesis — How Pneumonia Occurs

Step 1: Breach of Host Defenses

• High inoculum (aspiration)
• Highly virulent organisms (S. pneumoniae capsule evades phagocytosis)
• Impaired host defenses (viral infection→ epithelial damage; smoking; immunosuppression; intubation bypassing upper airway)

Step 2: Microbial Invasion of Alveolar Space

• Pattern recognition receptors (TLRs) recognize bacterial PAMPs
• Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) are released
• Massive neutrophil recruitment ensues
• The alveolar capillary membrane is disrupted → exudative fluid fills alveoli

Step 3: Morphologic Stages of Lobar Pneumonia (Robbins Pathology)

---

6. Physiological Effects on the Body

Pulmonary Effects

• Consolidated alveoli receive blood flow but contain no air → true intrapulmonary shunt (perfusion without ventilation)
• In mild-moderate pneumonia: shunt fraction ~7.5%, low V/Q regions ~4.2% → mild hypoxemia (PaO₂ ~74 mmHg)
• In severe pneumonia requiring mechanical ventilation: shunt fraction rises to ~21.9%, low V/Q regions to ~10.9%
• As consolidation worsens, both shunt and low V/Q areas increase; the greater the shunt fraction, the poorer the response to supplemental O₂
• Murray & Nadel's Respiratory Medicine (MIGET studies)

Systemic Inflammatory Response

• Bacteremia in 10–25% (especially S. pneumoniae)
• Sepsis → systemic vasodilation, third-spacing, hypotension, end-organ hypoperfusion
• SIRS criteria frequently met: fever/hypothermia, tachycardia, tachypnea, leukocytosis/leukopenia
• Progression to septic shock in ~5–10% of hospitalized CAP

Cardiac Complications

• Decompensated heart failure
• New atrial fibrillation or flutter
• Acute coronary syndrome (demand ischemia from hypoxia + inflammation)
• Stroke
• Goldman-Cecil Medicine, p. 991 (Prognosis section)

Pulmonary Complications

Other Systemic Effects

• Hyponatremia: SIADH (especially Legionella)
• Hepatic dysfunction: elevated transaminases from sepsis/hypoperfusion
• Renal impairment: AKI from sepsis, dehydration, nephrotoxic antibiotics
• Metabolic acidosis with multi-organ involvement

---

7. Clinical Presentation

Typical (Bacterial) Pneumonia

• Abrupt onset of fever (>38.5°C), rigors, productive cough with purulent/rust-colored sputum
• Pleuritic chest pain (parietal pleura involvement)
• Dyspnea proportional to extent of consolidation
• On auscultation: bronchial breath sounds, egophony (E→A change), increased tactile fremitus, dullness to percussion over consolidated area
• Chest X-ray: lobar or segmental consolidation, air bronchograms

Atypical Pneumonia (Mycoplasma, Chlamydophila, Legionella)

• Gradual onset over days
• Dry, non-productive cough; prominent extrapulmonary features (headache, myalgia, diarrhea, rash)
• CXR: diffuse bilateral interstitial/patchy infiltrates, worse than physical exam suggests
• "Walking pneumonia" — patient ambulatory despite bilateral infiltrates

Viral Pneumonia

• Respiratory distress out of proportion to radiologic signs
• Interstitial pattern on CXR/CT; ground-glass opacities
• Inflammation confined to alveolar septa; no consolidative exudate initially

Chest X-ray Patterns

---

8. Diagnosis

Clinical Criteria

• ≥1 respiratory symptom (cough, dyspnea, pleuritic pain) + radiographic opacity + no alternative diagnosis

Laboratory Workup

Imaging

• CXR: First-line; lobar consolidation, air bronchograms, pleural effusion
• CT thorax: More sensitive; reveals cavitation, empyema, pulmonary emboli; useful when CXR equivocal or no improvement after 72h

Severity Scoring — Site-of-Care Decision

• Score 0–1: Outpatient
• Score 2: Short hospital admission
• Score 3–5: ICU consideration

• Septic shock requiring vasopressors
• Invasive mechanical ventilation

---

9. Treatment

General Principles

• Empiric therapy based on disease severity, comorbidities, risk for drug-resistant organisms, and local antibiograms — per IDSA/ATS 2019 guidelines
• Time-to-antibiotics matters: each hour of delay in septic shock/hypotension increases mortality by 7–8%
• De-escalate based on cultures, procalcitonin trends, and MRSA nasal swab results

Outpatient Treatment (CURB-65 0–1, PSI Class I–II)

Inpatient — Non-ICU (CURB-65 2–3, PSI Class III–IV)

• Observational studies show fluoroquinolone monotherapy achieves 30–45% relative mortality reduction vs. β-lactam alone for hospitalized CAP
• Duration: 5 days in clinically stable patients (afebrile ≥48h, tolerating PO, SpO₂ ≥90% on room air)

Inpatient — ICU / Severe CAP

Hospital-Acquired Pneumonia (HAP) / VAP

• Risk-stratify for MDR organisms (prior antibiotics within 90 days, hospitalization >5 days, prior MDR isolation, immunosuppression)
• Low MDR risk: piperacillin-tazobactam OR ceftriaxone OR levofloxacin
• High MDR risk: two anti-pseudomonal agents (e.g., pip-tazo + aminoglycoside OR fluoroquinolone) + vancomycin or linezolid for MRSA
• "PES pathogens" (Pseudomonas, ESBL-Enterobacterales, MRSA) account for up to 6% of hospitalized CAP but require broader spectrum coverage

Supportive Treatment (All Severities)

Treatment Failure — When to Reassess (Goldman-Cecil, Table 85-7)

1. Wrong antibiotic choice or inadequate dosing
2. Drug-resistant organism (not covered by empiric regimen)
3. Loculated empyema requiring drainage
4. Endobronchial obstruction (cancer, foreign body)
5. Non-infectious mimics: PE, malignancy, cryptogenic organizing pneumonia, heart failure

---

10. Duration of Therapy

---

11. Recovery Timeline

Outpatient (Mild CAP)

• Fever resolves: 2–4 days
• Cough improves: 5–14 days
• Fatigue may persist: 2–4 weeks
• Radiographic clearing: 4–8 weeks (longer in elderly, lobar pneumonia, bacteremic disease)
• Return to normal activity: 1–3 weeks
• Prognosis for full recovery is excellent for outpatients — Goldman-Cecil Medicine, p. 991

Hospitalized Patients

• ~85% of hospitalized patients respond within 7 days: improved cough and dyspnea, afebrile, tolerating oral intake → in-hospital mortality 1%, 30-day mortality 5%
• All-cause mortality:
  • In-hospital: ~6%
  • 30-day: ~13%
  • 6-month: ~23%
  • 1-year: ~30% (reflects comorbidities and underlying frailty)
• 70% discharged home (~one-third need home health follow-up); 30% discharged to nursing home or rehabilitation
• 30-day readmission rate: ~15% (higher in those requiring home health)
• Goldman-Cecil Medicine, p. 991

Predictors of Delayed Recovery / Poor Outcome

• Need for ICU at presentation
• Obesity, diabetes, active malignancy
• Age ≥65
• Bacteremia
• Causative organisms: MRSA, Legionella, Gram-negatives
• Delayed appropriate antibiotics

Mycoplasma Pneumonia Recovery

• Usually benign, self-limited with excellent prognosis
• Hospitalized adults: 8% mortality, particularly elderly
• ARDS/death rare
• Murray & Nadel's Respiratory Medicine

---

12. Prevention

---

Summary for Quick Reference

PNEUMONIA AT A GLANCE
─────────────────────────────────────────────────────────────
Definition:    Acute lung parenchyma infection + imaging opacity
Top CAP bug:   S. pneumoniae → lobar consolidation, bacteremia
Top HAP bug:   S. aureus (MRSA), Pseudomonas, Gram-negatives
Pathophysiology: Intrapulmonary shunt → V/Q mismatch → hypoxemia
Key stages:    Congestion → Red hepatization → Gray hepatization → Resolution
Severity tool: CURB-65 (0-1: outpatient; 2: admit; 3-5: ICU)
Mild CAP Rx:   Amoxicillin 1g TID × 5d OR Doxycycline × 5d
ICU CAP Rx:    β-lactam + macrolide ± MRSA/anti-Pseudomonal cover
Duration:      5 days (outpatient/non-severe) to 7-14 days (severe/special bugs)
85% respond:   Within 7 days of hospitalization
30-day mortality: ~5% (outpatient) → ~13% (hospitalized)
Vaccine:       PCV20 ≥65y, annual influenza
─────────────────────────────────────────────────────────────

---

• Goldman-Cecil Medicine International Edition, Chapter 85: Overview of Pneumonia
• Robbins & Kumar Basic Pathology, Chapter: Community-Acquired Pneumonia
• Fishman's Pulmonary Diseases and Disorders, Chapters 122, 125, 129: CAP guidelines, antibiotic principles
• Murray & Nadel's Textbook of Respiratory Medicine: Gas exchange in pneumonia (MIGET studies)
• Rosen's Emergency Medicine: Pediatric pneumonia chapter